Literature DB >> 16855915

Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone.

K Schwartz1, I Herman, G Peer, A Weizman, M Rehavi.   

Abstract

The brain vesicular monoamine transporter (VMAT2) is essential for neuronal monoamine storage and regulation of monoaminergic neurotransmission. We demonstrated previously a high degree of similarity between the pharmacodynamic characteristics of platelet and brain VMAT2. Opioids induce increase of dopamine release in limbic structures. In the present study we assessed the VMAT2 pharmacodynamic characteristics using high affinity [(3)H]dihydrotetrabenazine (TBZOH) binding to platelets of former male heroin addicts maintained on methadone (n = 12) compared to age-matched healthy controls (n = 13). A significant increase (19%, p < 0.05) in platelet VMAT2 density (Bmax) was observed in the methadone treated patients compared to controls. There was no significant difference in the affinity of [(3)H]TBZOH to its platelet binding site. The increased VMAT2 density may reflect a compensatory attempt to prevent vesicular depletion due to chronic methadone exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855915     DOI: 10.1007/s00702-006-0527-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  24 in total

Review 1.  The dopamine hypothesis of reward: past and current status.

Authors:  R Spanagel; F Weiss
Journal:  Trends Neurosci       Date:  1999-11       Impact factor: 13.837

Review 2.  The transport of neurotransmitters into synaptic vesicles.

Authors:  R H Edwards
Journal:  Curr Opin Neurobiol       Date:  1992-10       Impact factor: 6.627

3.  The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).

Authors:  M Höltje; B von Jagow; I Pahner; M Lautenschlager; H Hörtnagl; B Nürnberg; R Jahn; G Ahnert-Hilger
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

4.  Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.

Authors:  M Zucker; A Weizman; M Rehavi
Journal:  Life Sci       Date:  2001-09-28       Impact factor: 5.037

5.  Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects.

Authors:  J K Zubieta; S F Taylor; P Huguelet; R A Koeppe; M R Kilbourn; K A Frey
Journal:  Biol Psychiatry       Date:  2001-01-15       Impact factor: 13.382

6.  The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake.

Authors:  Markus Höltje; Sandra Winter; Diego Walther; Ingrid Pahner; Heide Hörtnagl; Ole Petter Ottersen; Michael Bader; Gudrun Ahnert-Hilger
Journal:  J Biol Chem       Date:  2003-02-25       Impact factor: 5.157

7.  Striatal dopaminergic and serotonergic markers in human heroin users.

Authors:  S J Kish; K S Kalasinsky; P Derkach; G A Schmunk; M Guttman; L Ang; V Adams; Y Furukawa; J W Haycock
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

8.  Binding of [3H]dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organelles.

Authors:  A M Cesura; B Bertocci; M Da Prada
Journal:  Eur J Pharmacol       Date:  1990-09-04       Impact factor: 4.432

9.  Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts.

Authors:  T Macedo; C A Ribeiro; D Cotrim; P Tavares; M T Morgadinho; M Caramona; M T Vicente; L Rodrigues; M G Cardoso; M L Keating
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

Review 10.  Brain dopamine and reward.

Authors:  R A Wise; P P Rompre
Journal:  Annu Rev Psychol       Date:  1989       Impact factor: 24.137

View more
  1 in total

1.  Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2015-07-31       Impact factor: 2.533

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.